Navigation Links
Publication in peer-reviewed journal highlights RESPeRATE as effective hypertension treatment
Date:4/22/2009

New York, N.Y.April 22, 2009InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that RESPeRATEthe only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertensionis highlighted as an effective treatment for high blood pressure in the April issue of the Journal of the American Academy of Nurse Practitioners.

The article, written by Elayne DeSimone, ANP, PhD, encourages the entire clinical community, in particular nurse practitioners and physician assistants, to provide individual attention and discuss non-traditional methods when treating patients who suffer from hypertension.

"A patient needs to fully understand his or her individual degree of risk, as well as the consequences of remaining untreated, to feel motivated to take an active part in their healthcare and be compliant with treatment," says DeSimone. "Seven out of 10 patients are not able to achieve their lower blood pressure goals with medication alone, and it is critically important to inform patients of both drug and non-drug treatment options to effectively treat both hypertension and its potential co-morbidities."

In the article, DeSimone highlights the impact of the nurse practitioner as an important source of information and empowerment for the patient. Early detection, monitoring and treatment of hypertension can dramatically reduce the number of hypertensive Americans and have a substantial impact on its associated consequences, both clinically and economically. Promotion of patient awareness and communication, coupled with a blend of drug and non-drug therapies can maximize the effect of a blood pressure treatment regimen.

Diet, exercise and adjunctive treatments are discussed as a way to help patients develop a new routine that fits into their lifestyles and improve treatment compliance. RESPeRATE is highlighted by DeSimone as a treatment that has been proven in multiple clinical studies to produce a significant and lasting decrease in blood pressure, averaging a reduction of 14 points systolic and 8 points diastolic.

"This most recent acknowledgement of RESPeRATE as an effective treatment option for hypertension adds to a growing body of support within the clinical community," says Erez Gavish, president and CEO, InterCure. "Nurse practitioners are vital in providing the best care possible to patients and we hope that these essential caretakers will choose to educate patients about the importance of non-drug therapies such as RESPeRATE."


'/>"/>

Contact: Lisa Mokaba
intercure@schwartz-pr.com
781-684-0770
Schwartz Communications
Source:Eurekalert

Related medicine news :

1. Open access to health research publications
2. Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
3. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
4. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
5. Telemedicine publication expands coverage
6. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
7. Fry Construction Is Featured in Key Industry Publication
8. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
9. Nature publication on pain research
10. Bojan M. Kuure Recognized by Strathmores Whos Who Worldwide Publication
11. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: